-
Lancet Oncol: Treatment of malignant thoracic mesothelioma with radiotherapy followed by a full pulmonary excision of the thoracic membrane
Time of Update: 2021-01-23
A new treatment for malignant thoracic mesothelioma, known as post-radiation mesothelioma surgery (SMART), a short-term accelerated course of treatment (IMRT) with a large dose of semi-open chest-tone radiotherapy, followed by a full lung excision outside the thoracic membrane.
-
J Immunother Cancer: Obesity weakens the effectiveness of anti-PD-1 immunotherapy in patients with kidney cancer
Time of Update: 2021-01-23
the frequency of immersive PD-1high CD8 plus T cells in tumor tissue in patients with primary kidney cancer was reduced, and the results were validated in mouse models.
-
Ann Oncol: Issue 3 | Pabosini s endocrine therapy vs chemotherapy for metastatic breast cancer that is resistant to ER-HER2-aromatase inhibitors
Time of Update: 2021-01-23
the trial was adjusted to include queue 2 (C2) after new evidence of a mutation in the estrogen-1 (ESR1) mutation that led to AIs resistance was found, and the patient received 1:1 treatment from Pabosini Combined Fluvis group or carpatebine.
-
Ann Oncol: The efficacy and safety of the new anti-CTLA4 antibody Quavonlimab combined with Pim monoantigen first-line treatment of NSCLC
Time of Update: 2021-01-23
In the dose increment (DE) phase: patients with advanced/metastasis solid tumors receive an initial flat dose of Quaponlimab as a single treatment of 25 mg (queue 1), 75 mg (queue 2) or 200 mg (queue 3), followed by a total of 4 courses of treatment at the same dose of Quavonlimab-Pim monoantigen (Q3W).
-
Ann Oncol: Issue 3 | Nirapali maintains efficacy in treating patients with platinum-sensitive relapse ovarian cancer in China
Time of Update: 2021-01-23
, Nirapali maintenance therapy reduced the risk of disease progression or death in patients with platinum-sensitive relapsed ovarian cancer by 68 percent compared to placebo, while extending PFS.
-
Ann Oncol: Issue 3 | Two standard complementary chemotherapy for stomach cancer and one standard chemotherapy for the efficacy of PK!
Time of Update: 2021-01-23
SOX or SOX/RT-assisted therapy can effectively extend DFS compared to S-1 single therapy in GC patients with D2 excision, stage II/III, and positive lymph nodes.
-
JCO: Phase 3 trial at Peking University Cancer Hospital reveals the clinical benefits of multi-departmental combined treatment of metastatic stomach cancer
Time of Update: 2021-01-23
This is an open randomized controlled phase 3 trial conducted at Peking University Cancer Hospital, which recruited previously untreated metastasis EGC patients to be randomized to the Early Interdisciplinary Support Therapy Joint Standard Therapy (ESC) or Standard Treatment (EC) group at 2:1.
-
Ann Oncol: The efficacy of Olapali monotherapy in patients with primary treatment for triple negative breast cancer
Time of Update: 2021-01-23
in tumors that did not carry HR mutations, 6/8 respondents and 3/13 non-responders showed BRCA1 high methylation (P-0.03).
excluded 1 gPALB2 and 4 gBRCA1/2 mutant carriers, 12/14 respondents (85.7%) and 3/13 non-respondents (23.1%, P-0.002) carry body cell HR mutations and/or BRCA1 methylation.
-
Eur J Cancer: The clinical benefits of ctDNA as a biomarker for stage 4 colorectal cancer
Time of Update: 2021-01-23
For patients with metastatic colorectal cancer, strated therapy (surgery or chemotherapy) is usually based on rough clinical pathological characteristics, such as tumor size and number of lesions.
through literature search, screening studies on IV.stage colorectal cancer ctDNA testing and clinical prognostofectomy (radiotherapy response, secondary excision rate, PFS, DFS, or OS).
-
Eur Radiol: How does metastasis occur in front of non-small cell lung cancer patients without invasive accuracy?
Time of Update: 2021-01-23
A paper published recently on Eur Radiol called Machine learning-based diagnostic method of pre-18 F-FDG PET/CT for evaluating mediastinal lymph nodes in non-cell lung cancer by using 18F-fluoride deoxygenated glucose (FDG) electron emission fault scanning/computer fault scanning (PET/CT) establishes the best machine learning (ML) model to evaluate metastatic lymph nodes (MedLNs) of non-small cell lung cancer and compare the diagnosis with that of a nuclear medicine physician.
-
Heavy discovery | God's journal CA announces the reasons for the decline in cancer deaths in the United States!
Time of Update: 2021-01-23
although the risk of lung cancer from smoking was small, the incidence of non-smoking-related lung cancer was much higher in women than in men.
same time, the overall death rate in the United States fell by 7.7 percent between 2014 and 2018, 46 percent of which was due to lung cancer.
-
Nat Commun: In-tumor immune heterogeneity (ITH): a sign of the development of hepatocellular carcinoma and tumor evolution
Time of Update: 2021-01-23
researchers found important spatial and esopic immune ITH in multiple tumor sites and explained its relationship to tumor evolution and disease development in the HCC.
-
Gastroenterology: The co-activation regulation of ZEB1 and YAP1 zinc dependence plays an important role in pancreatic cancer metastasis
Time of Update: 2021-01-23
In human pancreatic cancer cells, clinical samples, spontaneous mouse models (KPC and KPCZ), in-place xeno-transplant models, 3D spherical and organ-like models, the interaction between cancer-promoting zinc finger transporter ZIP4, zinc-dependent EMT transcription factor ZEB1, co-activation factor YAP1 and integrator alpha3 (ITGA3) was observed.
-
Int J Cancer: The correlation between sleep time and 22 cancer risks
Time of Update: 2021-01-23
, the study did not provide strong evidence to support a causal relationship between sleep duration and overall cancer and cancer risk in specific areas.
-
Clin Cancer Res: Small doses of tymoxifen can effectively reduce the risk of breast cancer in breast radiation-treated cancer survivors
Time of Update: 2021-01-23
Low doses of tymoxifen reduce the risk of breast cancer, but have not yet been tested in cancer survivors who have received chest radiation -- a population with the same risk of breast cancer as individuals with BRCA mutations.
-
PNAS: Has Ray Gongto become a targeted drug? It is expected to be used to treat cancers with IDH1 mutations
Time of Update: 2021-01-23
In the history of medicine, there are many classic pharmaceutical ingredients from natural plants, such as the "unfailing willow" aspirin, "the change of god medicine" metformin. So now, we're looking
-
Annl Oncol: CtDNA state's ability to predict breast cancer treatment remission and recurrence
Time of Update: 2021-01-23
during NAC, personalized ctDNA monitoring for patients with high-risk early-stage breast cancer may help to assess treatment relief in real time and help fine-tune pCR as an alternative endpoint for survival prognostication.
-
Ann Oncol: The efficacy of alpelisib-fluvis group therapy for PIK3CA mutant HR-HER2-advanced breast cancer
Time of Update: 2021-01-23
the prognostication of patients in the total population was 39.3 months in the PIC3CA mutation queue (n-341), the mid-OS of the Apellis-Fluvis group and the placebo-fluvis group were 39.3 months (95% CI 34.1-44.9) and 31.4 months (26.8-41.3) (risk ratio of 0.86, 95% CI 0.64-1.15; OS results did not exceed the pre-specified efficacy threshold.
-
BMC Medicine: More than 300,000 people are at higher risk of death from drinking and not eating!
Time of Update: 2021-01-23
In the risk assessment of alcohol type and health, drinking spirits and beer/cider and mortality, significant cardiovascular events, cirrhosis and the risk of accident/self-harm increased significantly compared to drinking red wine.
-
JCO Precision Oncol: NTRK fusion is more common in childhood tumors than expected
Time of Update: 2021-01-23
in a large study of childhood cancer patients published recently in the journal JCO Precision Oncology, researchers at Children's Hospital of Philadelphia (CHOP) analyzed the frequency, fusion partners, and clinical outcomes of the neurotrophic factor tyrosine-subject kinase (NTRK), a clinical biomarker that identifies patients suitable for treatment with FDA-approved TRK inhibitors.
